Seifert Oliver, Pollak Nadine, Nusser Anja, Steiniger Frank, Rüger Ronny, Pfizenmaier Klaus, Kontermann Roland E
Institut für Zellbiologie und Immunologie, Universität Stuttgart , Allmandring 31, 70569 Stuttgart, Germany.
Bioconjug Chem. 2014 May 21;25(5):879-87. doi: 10.1021/bc400517j. Epub 2014 May 7.
The TNF-related apoptosis-inducing ligand (TRAIL) is a powerful inducer of apoptosis in tumor cells; however, clinical studies with recombinant soluble TRAIL were rather disappointing. Here, we developed TRAIL-functionalized liposomes (LipoTRAIL, LT) to mimic membrane-displayed TRAIL for efficient activation of death receptors DR4 and DR5 and enhanced induction of apoptosis, which were combined with an anti-EGFR single-chain Fv fragment (scFv) for targeted delivery to EGFR-positive tumor cells. These immuno-LipoTRAILs (ILTs) bound specifically to EGFR-expressing cells (Colo205) and exhibited increased cytotoxicity compared with that of nontargeted LTs. Compared to that of the soluble TRAIL, the plasma half-life of the functionalized liposomes was strongly extended, and increased antitumor activity of LT and ILT was demonstrated in a xenograft tumor model. Thus, we established a multifunctional liposomal TRAIL formulation (ILT) with improved pharmacokinetic and pharmacodynamic behavior, characterized by targeted delivery and increased induction of apoptosis due to multivalent TRAIL presentation.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是肿瘤细胞凋亡的有力诱导剂;然而,重组可溶性TRAIL的临床研究结果却相当令人失望。在此,我们开发了TRAIL功能化脂质体(LipoTRAIL,LT),以模拟膜展示的TRAIL,从而有效激活死亡受体DR4和DR5,并增强凋亡诱导作用,还将其与抗表皮生长因子受体单链Fv片段(scFv)结合,用于靶向递送至表皮生长因子受体阳性肿瘤细胞。这些免疫LipoTRAIL(ILT)特异性结合表达表皮生长因子受体的细胞(Colo205),与非靶向LT相比,表现出更高的细胞毒性。与可溶性TRAIL相比,功能化脂质体的血浆半衰期显著延长,并且在异种移植肿瘤模型中证明了LT和ILT的抗肿瘤活性增强。因此,我们建立了一种具有改善药代动力学和药效学行为的多功能脂质体TRAIL制剂(ILT),其特征在于靶向递送以及由于多价TRAIL呈现而增加的凋亡诱导作用。